Search Results

Amyris, Inc. announced financial results for the first quarter ended March 31, 2023.

Amyris, Inc. announced that it is moving forward with an operational and financial restructuring to further advance its ongoing strategic transformation and position the Company for long-term success.

Amyris, Inc. announced that it has completed the negotiation of key financial and business terms of the previously communicated strategic transaction for the exclusive rights to supply two of Amyris’ ingredients.

Amyris, Inc. announced that John Melo has resigned from his role as President & Chief Executive Officer and a member of the Board of Directors, effective immediately.

Amyris, Inc. today announced that it has signed an exclusive license agreement with British specialty chemicals company Croda International Plc, or the supply of sustainable squalene.

Amyris, Inc., a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-Market™ technology platform and clean beauty consumer brands, provided an update on first quarter revenue.

Amyris, Inc. announced that it has completed the previously announced strategic transaction with Givaudan SA for the worldwide exclusive licensing of certain cosmetic ingredients, including Neossance® Squalane, the highest performant emollient, Neossance® Hemisqualane, the plant-based silicone alternative, and CleanScreen™, the sustainable sun protector.

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world’s transition to sustainable consumption through its Lab-to-MarketTM technology platform and clean beauty consumer brands, today announced financial results for the fourth quarter and full year ended December 31, 2022.